Advertisement

Immunological Tests in Primary Sjögren Syndrome

  • Soledad Retamozo
  • Pilar Brito-Zerón
  • Myriam Gandía
  • Lucio Pallarés
  • Manuel Ramos-Casals
Chapter

Abstract

Patients with primary Sjögren syndrome (SS) produce a wide variety of autoantibodies directed at specific nuclear or cytoplasmic antigens. In some cases, the target antigen is present within specific tissues (Table 28.1). B-lymphocyte hyperactivation, the most typical etiopathogenic abnormality of primary SS, accounts for these autoantibodies. Autoantibodies have traditionally been central to classification criteria for SS. The 1993 European Criteria [1] included the presence of one or more of the following four antibodies: antinuclear antibodies (ANA), rheumatoid factor, anti-SSA/Ro, and anti-SSB/La. However, in the 2002 Criteria [2], only anti-SSA/Ro and anti-SSB/La antibodies were included. Together with a positive salivary gland biopsy, the presence of these autoantibodies became mandatory criteria for the classification of primary SS.

Keywords

Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Primary Biliary Cirrhosis Mixed Connective Tissue Disease Articular Involvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjogren’s syndrome. Arthritis Rheum. 1993;36:340–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.PubMedCrossRefGoogle Scholar
  3. 3.
    García-Carrasco M, Ramos-Casals M, Font J, Vives J. Interpretación de las pruebas inmunológicas en el síndrome de Sjögren. In: Ramos-Casals M, García-Carrasco M, Anaya JM, Coll J, Cervera R, Font J, Ingelmo M, editors. Síndrome de Sjögren. Barcelona: Masson; 2003. p. 445–66.Google Scholar
  4. 4.
    Fauchais AL, Lambert M, Launay D, Michon-Pasturel U, Queyrel V, Nguyen N, et al. Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 74 patients. Lupus. 2004;13:245–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Cervera R, Garcia-Carrasco M, Font J, Ramos M, Reverter JC, Munoz FJ, et al. Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol. 1997;15:361–5.PubMedGoogle Scholar
  6. 6.
    Zufferey P, Meyer OC, Bourgeois P, Vayssairat M, Kahn MF. Primary Sjögren syndrome ­preceding systemic lupus erythematosus: a retrospective study of 4 cases in a cohort of 55 SS patients. Lupus. 1995;4:23–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Satoh M, Yamagata H, Watanabe F, Nakayama S, Ogasawara T, Tojo T, et al. Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjogren’s syndrome. Lupus. 1995;4:63–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Hollingsworth PN, Pummer SC, Dawkins RL. Antinuclear antibodies. In: Peter JB, Shoenfeld Y, editors. Antibodies. Amsterdam: Elsevier; 1996. p. 74–90.Google Scholar
  9. 9.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.PubMedCrossRefGoogle Scholar
  10. 10.
    Adams BB, Mutasim DF. The diagnostic value of anti-nuclear antibody testing. Int J Dermatol. 2000;39:887–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sjögren’s syndrome. J Intern Med. 1996;239:475–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Wise CM, Woodruff RD. Minor salivary gland biopsies in patients investigated for primary Sjögren’s syndrome. A review of 187 patients. J Rheumatol. 1993;20:1515–8.PubMedGoogle Scholar
  13. 13.
    Shah F, Rapini RP, Arnett FC, Warner NB, Smith CA. Association of labial salivary gland histopathology with clinical and serologic features of connective tissue diseases. Arthritis Rheum. 1990;33:1682–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other ­systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36(4):246–55.PubMedCrossRefGoogle Scholar
  15. 15.
    Wenzel J, Gerdsen R, Uerlich M, Bauer R, Bieber T, Boehm I. Antibodies targeting extractable nuclear antigens: historical development and current knowledge. Br J Dermatol. 2001;145:w859–67.PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81:270–80.CrossRefGoogle Scholar
  17. 17.
    Davidson BKS, Kelly CA, Griffiths ID. Primary Sjogren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999;38:245–53.CrossRefGoogle Scholar
  18. 18.
    Moutsopoulos HM, Zerva LV. Anti-Ro (SS-A)/La (SS-B) antibodies and Sjogren’s syndrome. Clin Rheumatol. 1990;9 Suppl 1:123–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Alexander EL, Arnett FC, Provost TT, Stevens MB. Sjogren’s syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities and serologic hyperreactivity. Ann Intern Med. 1983;98:155–9.PubMedGoogle Scholar
  20. 20.
    Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjogren’s syndrome. Medicine (Baltimore). 1982;61:247–57.Google Scholar
  21. 21.
    Harley JB, Alexander EL, Bias WB, et al. Anti-Ro(SS-A) and anti-La(SS-B) in patients with Sjogren’s syndrome. Arthritis Rheum. 1986;29:196–206.PubMedCrossRefGoogle Scholar
  22. 22.
    Manoussakis MN, Tzioufas AG, Pange PJ, Moutsopoulos HM. Serological profiles in ­subgroups of patients with Sjogren’s syndrome. Scand J Rheumatol. 1986;61:89–92.Google Scholar
  23. 23.
    Markusse HM, Veldhoven CH, Swaak AJ, Smeenk RT. The clinical significance of the detection of anti-Ro/SS-A and anti-La/SS-B autoantibodies using purified recombinant proteins in primary Sjogren’s syndrome. Rheumatol Int. 1993;13:147–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Locht H, Pelck R, Manthorpe R. Clinical manifestations correlated to the prevalence of autoantibodies in a large (n  =  321) cohort of patients with primary Sjögren’s syndrome: a comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria. Autoimmun Rev. 2005;4:276–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Nardi N, Brito-Zerón P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol. 2006;25:341–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81:281–92.CrossRefGoogle Scholar
  27. 27.
    Wegelious O, Fyhrquist F, Adner PL. Sjogren’s syndrome associated with vitamin B12 ­deficiency. Acta Rheumatol Scand. 1970;16:184–90.Google Scholar
  28. 28.
    Williamson J, Paterson RW, McGavin DD, Greig WR, Whaley K. Sjogren’s syndrome in relation to pernicious anaemia and idiopathic Addison’s disease. Br J Ophthalmol. 1970;54:31–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Pedro-Botet J, Coll J, Tomás S, Soriano JC, Gutiérrez Cebollado J. Primary Sjogren’s syndrome associated with chronic atrophic gastritis and pernicious anemia. J Clin Gastroenterol. 1993;16:146–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362(9377):53–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Ramos-Casals M, Nardi N, Brito-Zeron P, et al. Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006;35:312–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren’s syndrome. Arthritis Rheum. 2004;50:882–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Isenberg DA. Systemic lupus erythematosus and Sjogren’s syndrome: historical perspective and ongoing concerns. Arthritis Rheum. 2004;50:681–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Bell DA. SLE in the elderly – is it really SLE or systemic Sjogren’s syndrome? J Rheumatol. 1988;15:723–4.PubMedGoogle Scholar
  35. 35.
    Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83:96–106.CrossRefGoogle Scholar
  36. 36.
    Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome. Semin Arthritis Rheum. 2000;29:296–304.PubMedCrossRefGoogle Scholar
  37. 37.
    Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Juby A, Johnston C, Davis P. Specificity, sensitivity and diagnostic predictive value of selected laboratory generated autoantibody profiles in patients with connective tissue diseases. J Rheumatol. 1991;18:354–8.PubMedGoogle Scholar
  39. 39.
    Habets WJ, de Rooij DJ, Salden MH, Verhagen AP, van Eekelen CA, van de Putte LB, et al. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol. 1983;54:265–76.PubMedGoogle Scholar
  40. 40.
    Kurata N, Tan EM. Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum. 1976;19:574–80.PubMedCrossRefGoogle Scholar
  41. 41.
    Tsuzaka K, Ogasawara T, Tojo T, et al. Relationship between autoantibodies and clinical parameters in Sjögren’s syndrome. Scand J Rheumatol. 1993;22:1–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Fujii T, Mimori T, Hama N, et al. Characterization of autoantibodies that recognize U4/U6 small ribonucleoprotein particles in serum from a patient with primary Sjögren’s syndrome. J Biol Chem. 1992;267:1641–6.Google Scholar
  43. 43.
    Setty YN, Pittman CB, Mahale AS, Greidinger EL, Hoffman RW. Sicca symptoms and anti-SSA/Ro antibodies are common in mixed connective tissue disease. J Rheumatol. 2002;29:487–9.PubMedGoogle Scholar
  44. 44.
    Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Manoussakis MN, Gharavi AE, Drosos AA, Kitridou RC, Moutsopoulos HM. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol. 1987;44:297–307.PubMedCrossRefGoogle Scholar
  46. 46.
    Asherson RA, Fei HM, Staub HL, Khamashta MA, Hughes GR, Fox RI. Antiphospholipid antibodies and HLA associations in primary Sjogren’s syndrome. Ann Rheum Dis. 1992;51:495–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Jedryka-Goral A, Jagiello P, D’Cruz DP, et al. Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren’s syndrome. Ann Rheum Dis. 1992;51:889–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164:77–82.PubMedCrossRefGoogle Scholar
  49. 49.
    Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J, Alarcon-Segovia D. Influence of disease duration, continued follow-up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 1993;20:437–42.PubMedGoogle Scholar
  50. 50.
    Haga HJ, Jacobsen EM, Peen E. Incidence of thromboembolic events in patients with primary Sjögren’s syndrome. Scand J Rheumatol. 2008;37:127–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicenter prospective study of 1000 patients. Medicine (Baltimore). 1999;78:167–75.CrossRefGoogle Scholar
  52. 52.
    Al Attia HM, D’Souza MS. Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports. Clin Rheumatol. 2003;22:70–2.PubMedCrossRefGoogle Scholar
  53. 53.
    Tubach F, Hayem G, Elias A, Nicaise P, Haim T, Kahn MF, et al. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma. Rev Rhum Engl Ed. 1997;64:362–7.PubMedGoogle Scholar
  54. 54.
    Tektonidou M, Kaskani E, Skopouli FN, Moutsopoulos HM. Microvascular abnormalities in Sjogren’s syndrome: nailfold capillaroscopy. Rheumatology (Oxford). 1999;38:826–30.CrossRefGoogle Scholar
  55. 55.
    Caramaschi P, Biasi D, Carletto A, et al. Sjögren’s syndrome with anticentromere antibodies. Rev Rhum Engl Ed. 1997;64:785–8.PubMedGoogle Scholar
  56. 56.
    Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol. 1994;19:298–302.PubMedCrossRefGoogle Scholar
  57. 57.
    Katano K, Kawano M, Koni I, Sugai S, Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjogren’s syndrome. J Rheumatol. 2001;28:2238–44.PubMedGoogle Scholar
  58. 58.
    Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X. Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34(11):2253–8.PubMedGoogle Scholar
  59. 59.
    Nishiya K, Chikazawa H, Hashimoto K, Miyawaki S. Antineutrophil cytoplasmic antibody in patients with primary Sjogren’s syndrome. Clin Rheumatol. 1999;18:268–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Font J, Ramos-Casals M, Cervera R, et al. Antineutrophil cytoplasmic antibodies in primary Sjögren’s syndrome: prevalence and clinical significance. Br J Rheumatol. 1998;37:1287–91.PubMedCrossRefGoogle Scholar
  61. 61.
    Gross WL, Schmitt WH, Csernok E. Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist’s perspective. Am J Kidney Dis. 1991;18:175–9.PubMedGoogle Scholar
  62. 62.
    Fukase S, Ohta N, Inamura K, Kimura Y, Aoyagi M, Koike Y. Diagnostic specificity of anti-neutrophil cytoplasmic antibodies (ANCA) in otorhinolaryngological diseases. Acta Otolaryngol Suppl. 1994;511:204–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Young C, Hunt S, Watkinson A, Beynon H. Sjogren’s syndrome, cavitating lung disease and high sustained levels of antibodies to serine proteinase 3. Scand J Rheumatol. 2000;29:267–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Hiromura K, Kitahara T, Kuroiwa T, et al. Clinical analysis of 14 patients with anti-myeloperoxidase antibody positive rapid progressive glomerulonephritic syndrome. Nippon Jinzo Gakkai Shi. 1995;37:573–9.PubMedGoogle Scholar
  65. 65.
    Hernandez JL, Rodrigo E, De Francisco AL, Val F, Gonzalez-Macias J, Riancho JA. ANCA-associated pauci-immune crescentic glomerulonephritis complicating Sjogren’s syndrome. Nephrol Dial Transplant. 1996;11:2313–5.PubMedGoogle Scholar
  66. 66.
    Tatsumi H, Tateno S, Hiki Y, Kobayashi Y. Crescentic glomerulonephritis and primary Sjogren’s syndrome. Nephron. 2000;86:505–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Akposso K, Martinant de Preneuf H, Larousserie F, Sraer JD, Rondeau E. Rapidly progressive acute renal failure. A rare complication of primary Sjogren syndrome. Presse Med. 2000;29:1647–9.PubMedGoogle Scholar
  68. 68.
    Radaelli F, Meucci G, Spinzi G, et al. Acute self-limiting jejunitis as the first manifestation of microscopic polyangiitis associated with Sjogren’s disease: report of one case and review of the literature. Eur J Gastroenterol Hepatol. 1999;11:931–4.PubMedCrossRefGoogle Scholar
  69. 69.
    Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273–81.PubMedCrossRefGoogle Scholar
  70. 70.
    Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50:709–15.PubMedCrossRefGoogle Scholar
  71. 71.
    Goëb V, Salle V, Duhaut P, et al. Clinical significance of autoantibodies recognizing Sjögren’s syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren’s syndrome. Clin Exp Immunol. 2007;148:281–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64:114–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjogren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol. 2005;24:673–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther. 2008;10:R51.PubMedCrossRefGoogle Scholar
  75. 75.
    Iwamoto N, Kawakami A, Tamai M, et al. Determination of the subset of Sjogren’s syndrome with articular manifestations by anticyclic citrullinated peptide antibodies. J Rheumatol. 2009;36:113–5.PubMedGoogle Scholar
  76. 76.
    Mohammed K, Pope J, Le Riche N, et al. Association of severe inflammatory polyarthritis in primary Sjögren’s syndrome: clinical, serologic, and HLA analysis. J Rheumatol. 2009;36:1937–42.PubMedCrossRefGoogle Scholar
  77. 77.
    Müller K, Manthorpe R, Permin H, Høier-Madsen M, Oxholm P. Circulating IgM rheumatoid factors in patients with primary Sjögren’s syndrome. Scand J Rheumatol Suppl. 1988;75:265–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Müller K, Oxholm P, Mier-Madsen M, Wiik A. Circulating IgA- and IgM-rheumatoid factors in patients with primary Sjögren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol. 1989;18(1):29–31.PubMedCrossRefGoogle Scholar
  79. 79.
    Ohara T, Itoh Y, Itoh K. Reevaluation of laboratory parameters in relation to histological findings in primary and secondary Sjogren’s syndrome. Nippon Naika Gakkai Zasshi. 2000;89:1337–42.PubMedCrossRefGoogle Scholar
  80. 80.
    Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 1996;39:767–72.PubMedCrossRefGoogle Scholar
  81. 81.
    Tzioufas AG, Manoussakis MN, Costello R, Silis M, Papadopoulos NM, Moutsopoulos HM. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjogren’s syndrome. Arthritis Rheum. 1986;29:1098–104.PubMedCrossRefGoogle Scholar
  82. 82.
    Ramos-Casals M, Cervera R, Yague J, et al. Cryoglobulinemia in primary Sjogren’s syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum. 1998;28:200–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–24.Google Scholar
  84. 84.
    Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002;46:741–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Lindgren S, Hansen B, Sjoholm AG, Manthorpe R. Complement activation in patients with primary Sjogren’s syndrome: an indicator of systemic disease. Autoimmunity. 1993;16:297–300.PubMedCrossRefGoogle Scholar
  86. 86.
    Alexander EL, Provost TT, Sanders ME, Frank MM, Joiner KA. Serum complement activation in central nervous system disease in Sjogren’s syndrome. Am J Med. 1988;85:513–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000;79:241–9.CrossRefGoogle Scholar
  88. 88.
    Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2005;44:89–94.CrossRefGoogle Scholar
  89. 89.
    Moriuchi J, Ichikawa Y, Takaya M, et al. Association of the complement allele C4AQ0 with primary Sjogren’s syndrome in Japanese patients. Arthritis Rheum. 1991;34:224–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Suzuki Y, Hinoshita F, Yokoyama K, Katori H, Ubara Y, Hara S, et al. Association of Sjogren’s syndrome with hereditary angioneurotic edema: report of a case. Clin Immunol Immunopathol. 1997;84:95–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Schoonbrood TH, Hannema A, Fijen CA, Markusse HM, Swaak AJ. C5 deficiency in a patient with primary Sjogren’s syndrome. J Rheumatol. 1995;22:1389.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Soledad Retamozo
    • 1
  • Pilar Brito-Zerón
    • 1
  • Myriam Gandía
    • 2
    • 3
  • Lucio Pallarés
    • 4
  • Manuel Ramos-Casals
    • 1
  1. 1.Spanish Group of Autoimmune Diseases (GEAS), Spanish Society of Internal Medicine (SEMI), Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune DiseasesICMD Hospital ClínicBarcelonaSpain
  2. 2.Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune DiseasesICMD Hospital ClínicBarcelonaSpain
  3. 3.Rheumatology DepartmentHospital Puerta del MarCadizSpain
  4. 4.Autoimmune Diseases UnitHospital Son EspasesPalma de MallorcaSpain

Personalised recommendations